Article
Strategies for mitigating emerging artemisinin-based antimalarial drug resistance in Rwanda: a promising approach for managing therapies in malaria-endemic countries.
BMJ global health - 2 Oct 2025
Muvunyi Claude Mambo, Gashema Pierre, Mbituyumuremyi Aimable, Iradukunda Patrick Gad, Siddig Emmanuel Edwar, Niyonzima Jean Damascene, Hakizimana Emmanuel, Umulisa Noella, Noor Abdisalan Mohamed, Mugabo Semahore Jules, Tuyishime Albert, Harelimana Jean de Dieu, Umuhire Jeanne, Butera Yvan, Nsanzimana Sabin
Abstract excerpt
Malaria treatment failures associated with reduced efficacy of chloroquine (CQ) and amodiaquine (AQ) antimalarial drugs emerged in Rwanda during the 1980s, prompting the policy shift towards adopting artemisinin-based combination therapies in 2006 as an alternative. However, recent findings from malaria surveillance and therapeutic efficacy studies have revealed a countrywide increase in antimalarial drug...
Read the complete abstract on PubMedTopics
- Antimalarials
- Artemisinins
- Humans
- Rwanda
- Drug Resistance
